ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ENOV / insiders
CDRE (62) ESTA (26) AVR (22) ZJYL (46) ⌘ Pro Terminal β†’

Enovis Corporation (ENOV) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$20.62 +3.57% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.71

Enovis Corporation (ENOV) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $1.15B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ENOV Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ENOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Enovis Corporation (NYSE: ENOV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $20.62 (+3.57% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, ENOV ranks #503 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ENOV compare to CDRE and ESTA in the Health Care sector?
β–Ό

Within the Health Care sector (Industrial Specialties), ENOV carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -32.7%. By comparison, CDRE (Cadre Holdings Inc.) holds a C grade (62/100 RQD, P/E 30.2x, ROIC 11.0%, cap $1.30B) and ESTA (Establishment Labs Holdings Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -15.8%, cap $1.86B). Among the 5-stock peer group, CDRE leads on earnings multiple (30.2x) while CDRE leads on capital efficiency (11.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ENOV?
β–Ό

Per ENOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001420800), Enovis Corporation generated $2.25B in revenue (+6.7% YoY), -$1.18B in net income, and $19.9M in free cash flow against $3.83B in total assets and $1.26B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.71 (+0.45%)🧬 Disciplined Float (+1.08% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (38/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (8)Whales (7)SEC (10)Macro (5)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$34 Bull$19 Base$15 Bear
πŸ“¬ FREE ENOV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ENOV)Realized 20D OHLCV Swing Band: Β±11.3%
Deterministic 5-Pillar Attribution (38/100 Composite)
πŸ” WHY ENOV SCORES 38/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 7/9

β–² #2 Bullish Driver: Cash Engine Quality+8/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0.9% FCF Margin ($19.9M FCF) & 59.8% Gross Margin

β–Ό #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (48.2) create a -15 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
30
Grade E$18.99+9% Next Q
Q2 (-2Q)
33
Grade E$20.69+4.1% Next Q
Q3 (-1Q)
35
Grade E$21.54-4.3% Next Q
Current
38
Grade D-$20.62-7.8% Hist 90D Ξ±
Trajectory: E (30) β†’ D- (38)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ENOV Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ENOV currently carries a cautious 38/100 (D-) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.84) and Max Pain ($21.65) forces dealer call-delta covering toward $34.03.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENOVβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œENOV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

ENOV Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ENOV)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ENOV. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENOV)

  • βœ“Walkthrough of ENOV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ENOV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.65%β–Ό DESCENDING CHANNEL
2026-11-03O $22.81H $22.81L $19.91C $20.62VOL 2.52M
RES: $22.56SUP: $16.07SMA50: $19.84SMA200: $23.05
$32.72$28.38$24.04$19.69$15.35RES $22.56SUP $16.07$20.622026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENOV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ENOV Butterfly Map β†’ + Track ENOV β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ENOV today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ENOV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ENOV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENOV)

Health Care Rank #503 of 1015 βš”οΈ CDRE vs ENOV Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ENOV vs. CDRE, ESTA, AVR, ZJYL)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Enovis Corporation (ENOV) ranks #503 by composite RQD confidence (38/100, grade D-) and #337 by equity capitalization ($1.15B). Within this direct 5-issuer industry benchmark cohort, CDRE leads on earnings valuation at 30.2x trailing P/E, while CDRE leads on capital efficiency and profitability with 11.0% ROIC and 42.5% gross margin. CDRE currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with ENOV at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ENOV ACTIVE
Enovis Corporation
D- 38/100 β€” 59.8% -32.7% +3.57% $1.15B Benchmark Subject
CDRE
Cadre Holdings Inc.
C 62/100 30.2x 42.5% 11.0% +3.79% $1.30B /cdre-vs-enov β†’
ESTA
Establishment Labs Holdings Inc.
E 26/100 β€” 69.3% -15.8% -2.22% $1.86B /esta-vs-enov β†’
AVR
Anteris Technologies Global Corp.
E 22/100 β€” 70.3% -35.0% -8.40% $615.2M /avr-vs-enov β†’
ZJYL
JIN MEDICAL INTERNATIONAL LTD. (Class A)
D 46/100 β€” 29.2% β€” -6.38% $371.8M /zjyl-vs-enov β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001420800 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enovis Corporation (ENOV) reported GAAP revenue of $2.25B (+6.7% vs. FY2024 revenue of $2.11B , and +31.7% cumulative change since FY2023) , GAAP net income of -$1.18B, operating cash flow of $217.3M, and free cash flow of $19.9M (+129.6% YoY). On the balance sheet, ENOV closed FY2025 with $3.83B in total assets against $1.26B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.25B -$1.18B $217.3M $19.9M $3.83B $1.26B
FY2024 (FY) 2024-12-31 $2.11B -$825.5M $113.5M -$67.2M $4.72B $1.31B
FY2023 (FY) 2023-12-31 $1.71B -$33.3M $135.0M $135.0M β€” β€”

3. ENOV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Enovis Corporation (NYSE: ENOV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $20.62 (+3.57% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, ENOV ranks #503 in composite RQD confidence.

How does ENOV compare to CDRE and ESTA in the Health Care sector?

Within the Health Care sector (Industrial Specialties), ENOV carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -32.7%. By comparison, CDRE (Cadre Holdings Inc.) holds a C grade (62/100 RQD, P/E 30.2x, ROIC 11.0%, cap $1.30B) and ESTA (Establishment Labs Holdings Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -15.8%, cap $1.86B). Among the 5-stock peer group, CDRE leads on earnings multiple (30.2x) while CDRE leads on capital efficiency (11.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ENOV?

Per ENOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001420800), Enovis Corporation generated $2.25B in revenue (+6.7% YoY), -$1.18B in net income, and $19.9M in free cash flow against $3.83B in total assets and $1.26B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ENOV trading relative to its 50-day, 200-day, and 52-week technical levels?

ENOV last traded at $20.62 (+3.57% on volume of 2,493,252 shares), positioning the stock +3.93% above its 50-day simple moving average ($19.84) and -10.54% below its 200-day simple moving average ($23.05). Across its 52-week range of $16.70 to $32.41, ENOV sits at the 25.0% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.3% ($18.29 to $22.95).

Direct Sub-Reports: ENOV RQD Cockpit ENOV 12M Forecast ENOV Earnings & Move ENOV Dividends & DRIP ENOV Insiders & 13F ENOV Whale Options ENOV Profit Sankey ENOV News & Why
ROARABLE RATING BRIEF β€’ RQD 38/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

ENOV β€” Enovis Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Enovis Corporation (ENOV) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $20.62 (+3.57% 1D, market capitalization $1.15B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -32.7%, gross margin of 59.8%, operating margin of -50.0%, and free cash flow yield of 1.51%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 7/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Enovis Corporation is listed on the NYSE and classified under the Health Care sector, within the Industrial Specialties industry,. Per the market data, the company reports a gross margin of 59.8%, but the source does not explain the underlying business activities that generate it.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Enovis Corporation (ENOV) reported $2.25B in annual revenue (up from $2.11B in FY2024, +6.7% YoY) and -$1.18B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.71B revenue, -$33.3M net income) through FY2025, ENOV scaled operating cash flow to $217.3M and free cash flow to $19.9M, backed by $3.83B in total assets against $1.26B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.51% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $16.70 – $32.41 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -50.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore β€” The only related signal in the feed is the acquisition-related price target cut and the M&A overhang referenced in headlines, which an investor may wish to track for ripple effects on leverage and capital allocation, though the source does not quantify these.

  • Key Question #1: Can ENOV sustain or expand its -50.0% operating margin and -32.7% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.25B and free cash flow of $19.9M, how will capital allocation balance growth reinvestment against $1.26B in total debt?
  • Key Question #3: How sensitive is ENOV's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ENOV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Enovis Corporation (ENOV) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ENOV Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ENOV Bull vs. Bear Conversation Board β€” What's Your Call at $20.62?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ENOV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ENOV:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $23.10 (+16.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning (12/20 whale pillar) and a Piotroski F-Score of 7/9 suggest some financial-quality a

Picked up a starter position in ENOV in my $100K Virtual Cash book at $19.91. Institutional accumulation and options positioning (12/20 whale pillar) and a Piotroski F-Score of 7/9 suggest some financial-quality and sponsorship support beneath the distressed headline metrics.. Trading inside a $16.70–$32.41 52-week range with 1.51% FCF yield gives solid downside support if Industrial Specialties multiples expand this quarter.

EarningsSniper πŸ‚ BULL

Both sides have a point here β€” ENOV's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $15.53 (-22.0%)
Spot @ $19.91

ROIC of -32.7%, an Altman Z-Score of 0.2, and operating losses widening to -$1.12B against $1.26B of debt point to a financially st

Careful chasing ENOV at $19.91. ROIC of -32.7%, an Altman Z-Score of 0.2, and operating losses widening to -$1.12B against $1.26B of debt point to a financially stressed business with weak cash returns.. Gross margin is 59.8%, but operating margin is -50.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $15.53 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%